Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. British journal of cancer [Br J Cancer] Journal article | | Title | Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. | | Author(s) | Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM | | Institution | Department of Oncology, Istituto Scientifico San Raffaele, Via Olgettina, 60, Milan 20132, Italy. | | Source | Br J Cancer 2009 Jun 30. | | Abstract | Background:Asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF) is a vascular targeting agent exploiting a tumour-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13, overexpressed on tumour blood vessels. Significant preclinical synergy was shown between low doses of NGR-TNF and doxorubicin.
Methods:The primary aim of this phase I trial was to verify the safety of low-dose NGR-hTNF combined with doxorubicin in treating refractory/resistant solid tumours. Secondary objectives included pharmacokinetics (PKs), pharmacodynamics, and clinical activity. In all 15 patients received NGR-hTNF (0.2-0.4-0.8-1.6 mug m(-2)) and doxorubicin (60-75 mg m(-2)), both given intravenously every 3 weeks.
Results:No dose-limiting toxicity occurred and the combination was well tolerated. Around two cases of neutropenic fevers, lasting 2 days, and two cases of cardiac ejection-fraction drops, one asymptomatic and the other symptomatic, were registered. Only 11% of the adverse events were related to NGR-hTNF and were short-lasting and mild-to-moderate in severity. There was no apparent PK interaction and the shedding of soluble TNF-receptors did not increase to 0.8 mug m(-2). One partial response (7%), at dose level 0.8 mug m(-2), and 10 stable diseases (66%), lasting for a median duration of 5.6 months, were observed.
Conclusions:NGR-hTNF plus doxorubicin was administered safely and showed promising activity in patients pre-treated with anthracyclines. The dose level of 0.8 mug m(-2) NGR-hTNF plus doxorubicin 75 mg m(-2) was selected for phase II development.British Journal of Cancer advance online publication, 30 June 2009; doi:10.1038/sj.bjc.6605162 www.bjcancer.com. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19568235 |
|
|
| |
Advertise on this site.
| | |
|
